Our most advanced product candidate, roxadustat, is currently approved in China for the treatment of anemia in CKD patients on dialysis and patients not on dialysis and approved in Japan for the treatment of anemia in CKD patients on dialysis. Roxadustat is in global Phase 3 clinical development in the U.S. and Europe and in Phase 2/3 development in China for anemia associated with myelodysplastic syndromes (MDS), and in a Phase 2 U.S. trial for treatment of chemotherapy-induced anemia. The goal of these clinical studies is to evaluate the safety and efficacy of the first oral hypoxia-inducible factor prolyl hydroxylase inhibitor therapy for the treatment of anemia.

• FG-4592-082, Phase 3, Anemia in myelodysplastic syndrome (MDS) patients
  > Currently enrolling
• FG-4592-092, Phase 2, Anemia in chemotherapy induced anemia (CIA) patients
  > Currently enrolling